Br J Anaesth:心脏手术患者机械通气期间吸入性麻醉剂的功效和安全性评价

2017-05-12 tianxuexin MedSci原创

本项研究的目的是通过系统评价和荟萃分析评估挥发性麻醉剂对成人心脏手术患者术后镇静的疗效和安全性。

本项研究的目的是通过系统评价和荟萃分析评估挥发性麻醉剂对成人心脏手术患者术后镇静的疗效和安全性。

研究人员从MEDLINE,EMBASE,CENTRAL,Web of Science,临床试验注册管理机构,会议记录和所附文章的参考文献中检索了随机对照试验的文章。独立的审查人员通过预先设计好的形式进行提取数据,包括患者特征,术中麻醉类型,使用的吸入麻醉剂,统计结果。

使用Cochrane工具评估偏倚的风险,并使用GRADE方法评估证据的强度。进行了8项研究,共纳入了610例患者。七个研究偏倚风险较高,一个偏倚风险较低。在进入重症监护室(ICU)和镇静停药后拔管的时间分别为76 分钟[95%置信区间(CI)-150至-2,I2 = 79%]和74分钟(95%CI-126至 - 23,I2 = 96%)在使用挥发性麻醉剂镇静的患者中时间较短。 接受挥发性麻醉镇静的患者肌钙蛋白浓度比对照组低0.71 ng/ml(95%CI 0.23-1.2)。报告内的其他结果多种多样,不适合荟萃分析。

研究得出结论,挥发性麻醉镇静可能会使得心脏手术后拔管时间相对较短,但ICU观察时间或住院时间长短无变化。它与术后肌钙蛋白浓度显着降低有关,但其对不良心血管结局的影响是不确定的。需要使用意向性治疗分析的双盲随机试验进行进一步探究。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050683, encodeId=c0e9205068317, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 03 14:26:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633365, encodeId=968b1633365c3, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 12 10:26:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444210, encodeId=bc4f1444210a4, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun May 14 00:26:00 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-11-03 xiangyuzhou971

    #EST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2050683, encodeId=c0e9205068317, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 03 14:26:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633365, encodeId=968b1633365c3, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 12 10:26:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444210, encodeId=bc4f1444210a4, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun May 14 00:26:00 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-09-12 AspirantSuo

    #ANA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2050683, encodeId=c0e9205068317, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Nov 03 14:26:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633365, encodeId=968b1633365c3, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Sep 12 10:26:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444210, encodeId=bc4f1444210a4, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sun May 14 00:26:00 CST 2017, time=2017-05-14, status=1, ipAttribution=)]
    2017-05-14 huagfeg

    #评价#

    0